Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
Background: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin-piperaquine (DHP) for all species of mal...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
BioMed Central
2015
|
| _version_ | 1797079618369355776 |
|---|---|
| author | Poespoprodjo, J Fobia, W Kenangalem, E Lampah, D Sugiarto, P Tjitra, E Anstey, N Price, R |
| author_facet | Poespoprodjo, J Fobia, W Kenangalem, E Lampah, D Sugiarto, P Tjitra, E Anstey, N Price, R |
| author_sort | Poespoprodjo, J |
| collection | OXFORD |
| description | Background: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin-piperaquine (DHP) for all species of malaria. This study presents the temporal analysis of adverse outcomes in pregnancy and early life following this policy change. Methods: From April 2004 to May 2010, a standardized questionnaire was used to collect information from all pregnant women admitted to the maternity ward. A physical examination was performed on all live birth newborns. The relative risks (RR) and the associated population attributable risks (PAR) of adverse outcomes in women with a history of malaria treatment to the risk in those without a history of malaria during the current pregnancy were examined to evaluate the temporal trends before and after DHP deployment. Results: Of 6,556 women enrolled with known pregnancy outcome, 1,018 (16%) reported prior anti-malarial treatment during their pregnancy. The proportion of women with malaria reporting treatment with DHP rose from 0% in 2004 to 64% (121/189) in 2010. In those with history of malaria during pregnancy, the increasing use of DHP was associated with a 54% fall in the proportion of maternal malaria at delivery and a 98% decrease in congenital malaria (from 7.1% prior to 0.1% after policy change). Overall policy change to more effective treatment was associated with an absolute 2% reduction of maternal severe anaemia and absolute 4.5% decrease in low birth weight babies. Conclusions: Introduction of highly effective treatment in pregnancy was associated with a reduction of maternal malaria at delivery and improved neonatal outcomes. Ensuring universal access to arteminisin combination therapy (ACT) in pregnancy in an area of multidrug resistance has potential to impact significantly on maternal and infant health. |
| first_indexed | 2024-03-07T00:48:28Z |
| format | Journal article |
| id | oxford-uuid:85852427-27fd-45d4-a2b9-07f03d451958 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:48:28Z |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:85852427-27fd-45d4-a2b9-07f03d4519582022-03-26T21:58:07ZTreatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:85852427-27fd-45d4-a2b9-07f03d451958Symplectic Elements at OxfordBioMed Central2015Poespoprodjo, JFobia, WKenangalem, ELampah, DSugiarto, PTjitra, EAnstey, NPrice, RBackground: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin-piperaquine (DHP) for all species of malaria. This study presents the temporal analysis of adverse outcomes in pregnancy and early life following this policy change. Methods: From April 2004 to May 2010, a standardized questionnaire was used to collect information from all pregnant women admitted to the maternity ward. A physical examination was performed on all live birth newborns. The relative risks (RR) and the associated population attributable risks (PAR) of adverse outcomes in women with a history of malaria treatment to the risk in those without a history of malaria during the current pregnancy were examined to evaluate the temporal trends before and after DHP deployment. Results: Of 6,556 women enrolled with known pregnancy outcome, 1,018 (16%) reported prior anti-malarial treatment during their pregnancy. The proportion of women with malaria reporting treatment with DHP rose from 0% in 2004 to 64% (121/189) in 2010. In those with history of malaria during pregnancy, the increasing use of DHP was associated with a 54% fall in the proportion of maternal malaria at delivery and a 98% decrease in congenital malaria (from 7.1% prior to 0.1% after policy change). Overall policy change to more effective treatment was associated with an absolute 2% reduction of maternal severe anaemia and absolute 4.5% decrease in low birth weight babies. Conclusions: Introduction of highly effective treatment in pregnancy was associated with a reduction of maternal malaria at delivery and improved neonatal outcomes. Ensuring universal access to arteminisin combination therapy (ACT) in pregnancy in an area of multidrug resistance has potential to impact significantly on maternal and infant health. |
| spellingShingle | Poespoprodjo, J Fobia, W Kenangalem, E Lampah, D Sugiarto, P Tjitra, E Anstey, N Price, R Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| title | Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| title_full | Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| title_fullStr | Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| title_full_unstemmed | Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| title_short | Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| title_sort | treatment policy change to dihydroartemisinin piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes |
| work_keys_str_mv | AT poespoprodjoj treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT fobiaw treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT kenangaleme treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT lampahd treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT sugiartop treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT tjitrae treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT ansteyn treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes AT pricer treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes |